Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New knee fluid test aims to speed up arthritis diagnosis

NCT ID NCT05778162

Diagnosis Sponsor: Zimmer Biomet Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new panel called Synovasure RISC to see how well it helps doctors diagnose arthritis in the knee. Researchers collected fluid from the knees of 1000 people with pain or swelling. The goal was to check if the test results matched the doctor's suspected diagnosis and to build a sample bank for future research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,000 people

The number who actually took part.

Started

Feb 2023

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients experiencing knee pain and/or inflammation.

Ages

18 to 89 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with knee pain and/or inflammation and planned arthrocentesis Exclusion Criteria: * Patient is unwilling or unable to give oral consent * Patient has any condition that would, in the judgment of the Investigator, place the patient at undue risk or interfere with the study * Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant) * Patient had an arthrocentesis of the index joint less than 2 weeks from the planned arthrocentesis * Insufficient synovial fluid sample of \< 1.5 mL * Patient age \< 18 or \> 89

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthritis, inflammatory are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

arthritic joint disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthritis, inflammatory

Contacts and locations

Locations

  • Rothman Orthopaedic Institute

    Philadelphia, Pennsylvania, 19107, United States